Language

Dermatology Research

Partnering with Pace Dermatology

We have recently partnered with Pace Dermatology to bring more accessible and innovative dermatology treatments to patients in the South Sound and Pacific Northwest. Together, patients benefit from the research expertise of the MultiCare’s Institute for Research & Innovation and the highly-skilled, passionate clinical team at Pace Dermatology. 

Dermatology studies include, but are not limited to, the following therapeutic areas:

  • Psoriasis
  • Atopic dermatitis
  • Acne
  • And other conditions coming soon

Drs. Aaron and Andrew Pace lead Pace Dermatology – with locations in Tacoma and Lakewood. They are board certified in dermatology, so patients can expect the highest level of care. 

Please click here to learn more about Pace Dermatology.

Dermatology Studies Accepting Participants

Adult 

Atopic Dermatitis 

BREEZE-AD5

Study Number: ELI LILY I4V-MC-JAIW - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6990

Psoriasis

Novartis CAIN457A2324

Study Number: CAIN457A2324 - A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


OASIS-1

Study Number: I6T-MC-AMAK - A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992

Pediatrics

Atopic Dermatitis

Regeneron 1434

Study Number: R668-AD-1434 - An open-label extension study to assess the long-term safety and efficacy of Dupilumab in patients 6 months or older to <18 yers of age with atopic dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


Pediatric Atopic Dermatitis

Study Number: B7451012 - A phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of PF-04965842 monotherapy in subjects aged 12 years and older, with moderate to severe atopic dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


AD Extension Study

Study Number: B7451015 - A Phase 3 Randomized, Double-Blind, Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of PF04965842, with or without Topical Medications, Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


Liberty AD PRESCHOOL

Study Number: R668-AD-1539 - A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab In Patients Aged ≥6 Months to <6 Years With Severe Atopic Dermatitis

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


PFIZER B7451014

Study Number: B7451014 - A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992

Psoriasis

NOVARTIS CAIN4572310

Study Number: NOVARTIS CAIN4572310 - A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single-blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992